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Abstract
Background: The increasing prevalence of type 2 diabetes poses both clinical and public health challenges. Cost-
effective approaches to prevent progression of the disease in primary care are needed. Evidence suggests that intensive
multifactorial interventions including medication and behaviour change can significantly reduce cardiovascular
morbidity and mortality among patients with established type 2 diabetes, and that patient education in self-
management can improve short-term outcomes. However, existing studies cannot isolate the effects of behavioural
interventions promoting self-care from other aspects of intensive primary care management. The ADDITION-Plus trial
was designed to address these issues among recently diagnosed patients in primary care over one year.
Methods/Design: ADDITION-Plus is an explanatory randomised controlled trial of a facilitator-led, theory-based
behaviour change intervention tailored to individuals with recently diagnosed type 2 diabetes. 34 practices in the East
Anglia region participated. 478 patients with diabetes were individually randomised to receive (i) intensive treatment
alone (n = 239), or (ii) intensive treatment plus the facilitator-led individual behaviour change intervention (n = 239).
Facilitators taught patients key skills to facilitate change and maintenance of key behaviours (physical activity, dietary
change, medication adherence and smoking), including goal setting, action planning, self-monitoring and building
habits. The intervention was delivered over one year at the participant’s surgery and included a one-hour introductory
meeting followed by six 30-minute meetings and four brief telephone calls. Primary endpoints are physical activity
energy expenditure (assessed by individually calibrated heart rate monitoring and movement sensing), change in
objectively measured dietary intake (plasma vitamin C), medication adherence (plasma drug levels), and smoking status
(plasma cotinine levels) at one year. We will undertake an intention-to-treat analysis of the effect of the intervention on
these measures, an assessment of cost-effectiveness, and analyse predictors of behaviour change in the cohort.
Discussion: The ADDITION-Plus trial will establish the medium-term effectiveness and cost-effectiveness of adding
an externally facilitated intervention tailored to support change in multiple behaviours among intensively-treated
individuals with recently diagnosed type 2 diabetes in primary care. Results will inform policy recommendations
concerning the management of patients early in the course of diabetes. Findings will also improve understanding
of the factors influencing change in multiple behaviours, and their association with health outcomes.
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Background
Diabetes presents a global challenge to health and well
being. The total number of people with the condition
is projected to rise from 285 million in 2010 to
438 million in 2030 [1]. More than 2.5 million people in
the UK are estimated to have diabetes, and the condi-
tion is the leading cause of kidney failure, blindness in
adults, and amputations in the UK [2]. The condition
can affect mental health and well-being, and is a major
risk factor for heart disease and stroke, reducing life
expectancy on average by 10 years [3].
The clinical care of people with diabetes currently
consumes around 10% of the NHS budget, a total
exceeding £9 billion [2]. People with diabetes (or their
carers) are responsible for the day-to-day management
of their condition, which includes eating a healthy diet,
being physically active, taking medication as prescribed
and not smoking. There is scope for improvement in
the prevalence of health-promoting behaviours among
people at risk of and with diabetes [4-6]. Developing
effective approaches to prevent progression of the dis-
ease by intensification of primary care management,
including prescribing and organisation of services, and
by directly supporting individual patients in self care, is
important in tackling the growing public health burden
of type 2 diabetes [7,8].
Evidence to support behavioural interventions to reduce
cardiovascular risk
There is good evidence that the onset of diabetes can be
delayed, and cardiovascular risk factors reduced, by
intensive interventions targeting multiple behaviours
among large groups of individuals with impaired glucose
tolerance followed up over several years [9]. The lifestyle
interventions in these programmes were individually tai-
lored and delivered by case managers or nutritionists
with extended training. They drew on a range of theore-
tical perspectives and used techniques such as goal set-
ting and self monitoring. In these studies the risk of
diabetes was directly associated with change in lifestyle:
the more behavioural targets that the participants
achieved at follow-up, the lower their incidence of
diabetes [10,11].
It has been recognised for some time that well orga-
nised care, including regular recall and review of
patients, is associated with better outcomes [12]. More
recently, there is also evidence from primary care that
regular patient follow-up supported by prompting of
doctors, feedback on goal attainment, and continuing
medical education and guidelines can improve cardio-
vascular risk factors in patients followed 8 years from
diagnosis compared with routine care [13]. Later in the
disease trajectory there is evidence from secondary care
that intensive multifactorial intervention including pre-
scription of medication and behavioural advice com-
pared with routine care, can significantly reduce
cardiovascular mortality in patients with type 2 diabetes
and microalbuminuria after 8 years. The results showed
a 50% reduction in cardiovascular and microvascular
events in the intervention group compared with routine
care. However, the intervention had only minor effects
on carbohydrate and fat intake, and no significant differ-
ences were observed for self-reported smoking and exer-
cise habits between groups [14]. The Look AHEAD
(Action for Health in Diabetes) trial is a multi-centre,
clinic-based randomised trial comparing the effects of
an intensive lifestyle intervention with diabetes support
and education (control group) on cardiovascular risk
factors and major cardiovascular disease among 5,145
overweight or obese individuals with clinically-detected
type 2 diabetes [15]. Four-year results from the trial are
encouraging, with participants in the intensive lifestyle
arm achieving greater weight loss and greater improve-
ments in fitness, glycated haemoglobin, systolic blood
pressure, and HDL-cholesterol than those in the control
group. The intervention was very intensive and partici-
pants were followed up annually. Overall, the evidence
to date suggests that the greatest impact on cardiovascu-
lar risk is from intensified prescribing rather than
patient education or behavioural interventions [7,8].
Despite this there is widespread introduction of healthy
lifestyle facilitators, or health trainers, throughout
England [16].
Limitations to the evidence to support diabetes
management in primary care
While evidence from earlier studies is encouraging, it is
not clear which approaches or combinations can cost-
effectively support behavioural change in people with
newly or recently diagnosed type 2 diabetes in primary
care. Most of the studies that demonstrate benefits from
interventions targeting multiple behavioural risk factors
have been conducted in research clinics or specialist set-
tings. In particular it is unclear whether direct interven-
tion by specialist lifestyle trainers to facilitate behaviour
change can add significantly to intensive management
by core multidisciplinary primary care teams. In the pri-
mary care of type 2 diabetes there are now an increasing
number of trials of case management, and self-manage-
ment of diabetes that include a focus on key risk beha-
viours; lack of regular physical activity, unhealthy dietary
intake and smoking. Reviews of randomised studies
[17,18] support the effectiveness of patient self-manage-
ment training in improving the management of type 2
diabetes in the short term. However, the contents of
many interventions have not been clearly specified and
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measurement of quality of delivery or receipt is largely
lacking. It is thus difficult to unravel why the effective-
ness of behavioural interventions is so variable. With
longer follow-up (>6 months), some of the behavioural
interventions that used regular contact with patients for
reinforcement were effective in improving glycaemic
control. Educational interventions using a patient-
centred approach to goal setting and problem-solving
were more promising than didactic interventions in
improving glycaemic control, weight, and lipid profiles
[17-20]. Interventions based primarily on providing
information about how to behave to avoid negative
health outcomes are less effective than those using well-
specified behaviour change techniques, building on
participants’ own motivations within a psychological fra-
mework [21,22].
Most of these studies omit the behaviour of medica-
tion taking. Yet intensive use of multiple medications to
control cardiovascular risk factors has been a central
tenet of effective interventions to improve cardiovascular
outcomes in type 2 diabetes over the last ten years
[23,24]. Patients can find taking medication regularly
difficult, particularly for multiple drugs in asymptomatic
conditions [25,26], emphasising the need for interven-
tions to support medication taking as prescribed along-
side other health-related behaviours.
A major limitation of studies to date is the inability to
isolate the effects of behavioural interventions from other
aspects of intensified management including prescribing
and organisation of services. This applies to both the
effect of the intervention on behaviour, and the subse-
quent effect of behaviour change on clinical outcomes
such as cardiovascular risk. The measurement of the
behaviours themselves is a challenge, with the majority of
trials relying on self-report, which is imprecise and sus-
ceptible to recall bias. Few behavioural interventions spe-
cify a hypothesised mechanism of action of behaviour
change techniques, and only a minority measure beha-
viour and its hypothesised determinants along a specified
causal pathway. This has limited the ability to identify
active ingredients of interventions aimed at facilitating
behaviour change and maintenance [27] and to replicate
effective interventions in specific clinical settings.
No studies of behavioural management of type-2 dia-
betes in primary care early in the trajectory of the disease
have demonstrated effects on cardiovascular disease-
related events or mortality; economic analyses are absent
or limited; and few studies examine health-care utiliza-
tion or patient-centred outcomes such as quality of life
or functional status. Performance, selection, attrition, and
detection biases are common in the studies reviewed, and
external generalisability is often limited.
Large gaps thus remain in the evidence concerning
effectiveness and cost-effectiveness of interventions to
improve multiple cardiovascular risk factors among
patients with type 2 diabetes in primary care by beha-
vioural means [20,28]. It is unclear whether interventions,
based on theory and evidence from psychology [29,30]
and designed to facilitate and maintain changes in beha-
viour (physical activity, diet, medication adherence and
smoking), could be cost-effective among people detected
early in the trajectory of the disease. It is also unclear
how such interventions are best delivered within a health
service. The existing evidence points to the importance
of clinical and social context of both the patient and
practitioner in enabling or obstructing health-related
behaviour changes, and of a coherent approach by pri-
mary and secondary care [20]. The ADDITION-Plus trial
was established to address these gaps.
The ADDITION-Plus trial was originally established
within the intensive treatment group in the Cambridge
centre of the ADDITION study (Figure 1). In brief, the
Anglo-Danish-Dutch Study of Intensive Treatment of
people with newly diagnosed diabetes in primary care
(ADDITION) study was set-up in 2001 [31]. It is a pri-
mary care-based study consisting of a screening phase
followed by a pragmatic open-label cluster randomised
controlled trial comparing the effect on cardiovascular
risk of intensive multi-factorial therapy and theory-
based diabetes education delivered by practice nurses
(intensive treatment) with routine care in patients with
screen-detected diabetes.
The aim of ADDITION-Plus was to assess whether a
behaviour change intervention delivered by trained and
quality-assured lifestyle facilitators, external to the primary
care team, was a cost-effective addition to intensive treat-
ment and could achieve and maintain changes in impor-
tant health related behaviours (physical activity, dietary
change, medication adherence and smoking cessation)
when offered to people with recently diagnosed diabetes
already receiving intensive general practice based care. Fol-
low-up was at one year post-randomisation. The trial
recruited screen-detected type 2 diabetes patients from
within the ADDITION-Cambridge trial [32], and included
patients with type 2 diabetes clinically diagnosed within
the previous three years. As such, the ADDITION-Plus
trial allows estimation of the additional contribution of a
facilitator-led intervention to good practice care in the
optimisation of healthy behaviours and well-being, and to
the reduction in cardiovascular risk factors in individuals
with recently diagnosed diabetes.
ADDITION-Plus objectives
To quantify the effectiveness and cost-effectiveness of
adding a facilitator-led theory-based behaviour change
intervention to intensive treatment of screen- and
clinically- detected type 2 diabetes patients, and to ana-
lyse the psychological, socio-demographic and clinical
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predictors of behaviour change in the cohort. The fol-
lowing research questions are posed:
Trial analysis
1. Can a facilitator-led intervention, based on theory and
evidence from psychology, to increase and maintain
health-promoting behaviours (physical activity, dietary
change, taking medication and smoking cessation) achieve
clinically important and measurable change in these beha-
viours when offered to people with screen-detected dia-
betes and to those recently diagnosed with diabetes?
Primary outcomes include objectively measured physi-
cal activity, fruit and vegetable intake, medication adher-
ence, and smoking status.
Secondary outcomes include (i) a composite measure
of behaviour derived from the four primary outcomes;
(ii) self-reported behaviours; (iii) modelled cardiovascu-
lar risk (UKPDS risk engine, v3[33]); (iv) levels of indivi-
dual clinical risk factors; (v) functional status, health
utility and quality of life; and (vi) costs and cost-
effectiveness.
Cohort analysis
2. What and how changes were achieved in objectively
measured health behaviours and health outcomes across
the trial cohort?
2.1 What are the psychological, socio-demographic
and clinical predictors of self-reported and objec-
tively measured behaviour change?
2.2 What are the clinical consequences of behaviour
change?
Methods and Design
Design and setting
The ADDITION-Plus study is nested within the inten-
sive treatment arm of the ADDITION-Cambridge trial
with additional practices (n = 8) added to increase the
recruitment of recently diagnosed patients; see Figure 1
for details of study design and patient flows. Participants
were recruited from 34 general practices in urban, sub-
urban and rural Cambridgeshire, East Hertfordshire,
West Suffolk and North Essex areas of England. 239/
425 eligible screen-detected patients from ADDITION-
Cambridge study, and 239/684 patients clinically diag-
nosed within the previous 3 years were individually
randomised to receive intensive treatment alone or in
conjunction with a facilitator-led behaviour change
intervention.
Total population available for 
individual randomisation 
n=478 
26 practices nested within the intensive 
treatment arm of the ADDITION-Cambridge 
study, with n=425 screen-detected type 2 
diabetes patients invited to join the 
ADDITION-Plus trial 
239 patients agree to be randomised into 
ADDITION-Plus 
27 practices (19 ADDITION-Cambridge, 8 
non-ADDITION practices), with n=684 type 
2 diabetes patients diagnosed within the 
previous three years invited to join the 
ADDITION-Plus trial 
239 patients agree to be randomised into 
ADDITION-Plus 
Control group measured at baseline (n=239) 
118 screen detected participants 
121 participants diagnosed in previous 3 years 
Intervention group measured at baseline (n=239) 
121 screen detected participants 
118 participants diagnosed in previous 3 years 
Measured at one-year 
Figure 1 Design and participant flows in the ADDITION-Plus trial (Cambridge, UK).
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Ethical approval was obtained from the Eastern Multi-
Centre Research Ethics Committee (reference number:
02/5/54). Participants gave written informed consent to
take part in the study. ISRCTN 99175498.
Participants
Eligibility criteria (initially assessed by general practice
staff) included: age (40-69yrs) with type 2 diabetes fol-
lowing (i) screening in the ADDITION programme or
(ii) clinical diagnosis during the three previous years in
participating GP surgeries. Exclusion criteria included
women who were pregnant or lactating or anybody who
had a psychotic illness or an illness with a likely prog-
nosis of less than one year.
Individual randomisation of participants to one of two
carefully characterised interventions was independent of
intervention facilitators, study coordination and
measurement teams, and central using a partial minimi-
sation procedure that dynamically adjusted the randomi-
sation probabilities to balance stratifiers (age, sex and
general practice, and within screen-detected and clini-
cally-diagnosed subgroups: smoking, self-reported medi-
cation adherence [34] and BMI). The stratifiers were
individually weighted in order that those with more
categories (such as general practice) could achieve an
even distribution between the two arms. A random ele-
ment was included in the minimisation to allow a sound
basis for inference.
Intensive treatment (comparison arm)
The following features were added to routine multi-
disciplinary primary care of diabetes to achieve intensive
treatment in both trial groups:
1. Academic detailing for general practitioners and
practice nurses: A practice-based academic detailing ses-
sion for primary care teams was conducted by a local
diabetologist or GP opinion leader to describe the treat-
ment algorithms and targets, patient materials, and to
present the evidence underpinning intensive treatment.
2. Treatment algorithms: These were based on trial
data demonstrating the benefits of intensive treatment
of several cardiovascular risk factors in people with dia-
betes [35-38], and recommended medication within
licensed indications (Table 1). GPs were advised to con-
sider prescribing an angiotensin converting enzyme
(ACE) inhibitor to patients with a blood pressure≥120/
80 and either a previous cardiovascular event or at least
one other cardiovascular risk factor [39]. The remainder
of the intervention was based on the stepwise target-led
regimen from the Steno-2 study [23] aimed at optimis-
ing hyperglycaemia, hypertension, dyslipidaemia and
microalbuminuria. GPs were advised to consider pre-
scribing 75 mg of aspirin daily to patients without speci-
fic contraindications. Although targets for treatment
Table 1 Measures used at baseline and one year in the
ADDITION-Plus trial (Cambridge, UK)
Measures Baseline One
year
C I C I
Objectively measured health behaviours
Physical activity (ActiHeart) [47] X X
Dietary intake (plasma vitamin C concentration) X X X X
Medication adherence (plasma drug concentrations) X X
Smoking status (plasma cotinine concentration) X X
Self-reported health behaviours
Physical activity: EPAQ-2 [52], IPAQ [53] X X X X
Dietary intake: EPIC food frequency questionnaire [54] X X X X
Medication adherence:
All drugs during the last month [34] X X X X
Hypoglycaemic drugs during the last month [34] X X
Smoking status and alcohol consumption
(questionnaire)
X X X X
CVD risk
Modelled ten-year CVD risk: UKPDS risk engine, v3 [33] X X X X
Self-reported history of angina, heart attack and stroke X X X X
Biochemical measures
HbA1c, total cholesterol, HDL and LDL cholesterol,
triglyceride, urea and electrolytes, creatinine, albumin,
bilirubin, alanine amino transferanse (ALT), alkaline
phosphatase, aspartate aminotransference (AST),
thyroid stimulating hormone (TSH), urine albumin/
creatinine ratio
X X X X
Clinical measures
Waist circumference, height, weight, blood pressure,
pulse, body fat impedance and ECG
X X X X
Cardiorespiratory fitness measured using a sub-
maximal VO2 test [47]
X X
Rose angina questionnaire [55] X X
Neuropathy questionnaire (adapted from the Michigan
screening instrument) 1
X X X X
Health utility, functional status, quality of life, well-being, treatment
satisfaction and anxiety
Diabetes well-being (WBQ-28) [57] X X
SF-36 [74] X X
Diabetes-related quality of life (ADDQOL) [57] X X
Diabetes Treatment satisfaction (DTS) [57] X X
EuroQol EQ-5D [59] X X X X
Consultation and relational empathy measure (CARE)
[61]
X X
Spielberger Short form State anxiety inventory [60] X X X X
Assessment of diabetes services X X
Frequency of and views about self-monitoring of
blood glucose (DiGEM questionnaire [62])
X X
Beliefs about behaviour change, illness perceptions and habit
Beliefs about behaviour change: intention, perceived
behavioural control, behavioural beliefs (physical
activity, eating a low-fat diet; taking medication and
smoking cessation) [29]
X X X X
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were specified and classes of drugs recommended, where
there was a choice between individual drugs the decision
was made by the GPs and patients. The intensive treat-
ment protocol was revised after publication of the Heart
Protection Study [40] to include a recommendation to
prescribe a statin to all patients with a cholesterol level
of≥3.5 mmol/l.
3. Treatment targets: HbA1c <7% (with a recommen-
dation to initiate treatment at a threshold of 6.5%),
blood pressure≤135/85 mmHg, total cholesterol <5
mmol/l or < 4.5 mmol/l for people with a history of
ischaemic heart disease.
4. Audit and feedback: Interactive practice-based audit
and feedback sessions were organised around 6 and
14 months after the academic detailing session and
annually thereafter. They consisted of discussion of
overall achievement of treatment targets and optimisa-
tion of the management of individual patients.
5. Provision of glucometers for patients: Blood gluc-
ometers and training in their use were provided to the
primary care team. However, the decision to offer a
glucometer to a patient was left to practitioners.
6. Theory-based diabetes education: Practice nurses
were provided with theory-based education materials to
discuss with, and give to patients in order to provide a
shared framework for the causes, consequences and
treatment of diabetes (’Getting Started with Diabetes’).
The materials were developed by a multidisciplinary
team and drew on Leventhal’s Common-Sense Model
[41]. They cross-referred to ‘Diabetes for Beginners-Type
2’ a Diabetes UK publication [42] that was included in
the patient information pack. The materials stressed the
importance of a healthy lifestyle for the control of
diabetes and associated health problems and provided
targets for behaviour change. Specifically, participants
with a BMI > 28 kg/m2 were encouraged to lose 5-10%
of their body weight, and all participants to increase
physical activity gradually (recommendations to reach
the equivalent of 35 minutes of brisk walking per day
for 7 days per week), decrease the consumption of fatty
foods and sugar, increase the consumption of fruit,
vegetables, and whole grains, avoid excessive alcohol
intake, take their medication regularly, self-monitor
their blood glucose level (if applicable) and attend
annual health checks. Participants who smoked were
encouraged to stop.
7. Funding to support more frequent contact between
patients and practitioners: Practices received funding
equivalent to three 10-minute consultations with a GP
and three 15-minute nurse appointments per patient per
year.
8. Dietary counselling: GPs were recommended to
refer all newly diagnosed patients to a dietician.
Intervention group: Intensive treatment plus facilitator
led behaviour change intervention
Participants in this group received intensive treatment
(described above) plus a facilitator-led, individually tai-
lored behaviour change intervention, based on psycholo-
gical theory and evidence. The intervention was
delivered by trained lifestyle facilitators, who were not
part of the practice team. The facilitators used detailed
protocols for each contact with the participant and
received on-going supervision and feedback from a Clin-
ical Psychologist, informed by assessment of tape-
recorded consultations, enabling tight quality assurance
of intervention delivery. The intervention was designed
to build on the diabetes education delivered by practice
nurses and intensive treatment by the practice team.
The behaviours targeted in the intervention were physi-
cal activity, dietary intake, medication adherence, and
smoking cessation. Hypothesised mediators of behaviour
change targeted in the intervention included illness per-
ceptions based on Leventhal’s Common-Sense Model
[41] and beliefs about behaviour change based on the
Theory of Planned Behaviour (TPB) [29]. The interven-
tion targeted instrumental (e.g. health) and affective
beliefs about changing specific behaviours, (lack of)
encouragement by important others (subjective norm),
and perceived barriers and facilitators of behaviour
change (perceived behavioural control). The behaviour
change techniques used by the facilitators could be
mapped onto the TPB (e.g., giving information,
strengthening motivation), Operant Theory (identifying
cues for action and reinforcement of behaviour change
or effort), Carver and Scheier’s Control Theory (e.g.,
goal setting, action planning, self-monitoring) and
Table 1 Measures used at baseline and one year in the
ADDITION-Plus trial (Cambridge, UK) (Continued)
Illness perceptions (consequences and treatment
control sub-scales IPQ-R) [65]
X X X X
Diabetes knowledge1 X X
Habit [67]) in relation to physical activity and dietary
change
X X
Intervention evaluation
Facilitator assessment X
Skills in last 12 months in relation to lifestyle change
and medication taking1
X
Costs
Self-reported current medication/vitamins X X X X
Personal patient costs1 X X
Health service and medication use in the previous
three months (adapted from the Aberdeen Health
Service Research Unit questionnaire) 1
X X
C = control group; I = intervention group; 1 Questionnaire developed for the
study.
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Relapse Prevention Theory (e.g., preparing for and deal-
ing with setbacks) [29,43-45]. Facilitators taught patients
this range of self-regulatory skills to achieve behaviour
change and maintenance over time, which was sup-
ported by a manual describing the skills. Each patient
initially selected to work on the behaviour(s) they most
wanted to change and felt most confident about chan-
ging. The facilitator later discussed with them other
domains in which change was possible and encouraged
patients to consider setting additional goals. Interested
patients were offered pedometers and/or glucometers.
The intervention was delivered over one year at the par-
ticipants’ surgeries. It included a one-hour introductory
meeting followed by six 30-minute meetings and four
brief phone calls. Facilitators visited participant’s homes
or workplaces if it was not possible to meet in the
surgery.
Measurement
Table 1 shows the measures taken at each stage in the
ADDITION-Plus study. Baseline measurements were
carried out on all eligible patients including the comple-
tion of questionnaires, physiological and anthropometric
measures, and venesection. Similar measurements were
conducted one year after recruitment. Measurements
were undertaken at outpatient clinical research facilities
by trained staff following standard operational proce-
dures and unaware of participants’ study group alloca-
tion. Double data entry of all anthropometric and
questionnaire measures was undertaken by experienced,
independent agencies, blind to study group (Wyman
Dillon Research and Data Management, Bristol, UK and
Document Technologies and Imaging Solutions Ltd,
Chalgrove, Oxford, UK).
Objectively measured health behaviours
Physical activity was assessed at one-year using a com-
bined heart rate and movement sensor (Actiheart,
CamNtech, Cambridge, UK), which was worn continu-
ously for at least 4 days [46]. A graded treadmill walk
test was used for individual calibration of heart rate
[47], a procedure which also provides an estimate of
cardio-respiratory fitness by extrapolation of the HR-
VO2 relationship to age-predicted maximal heart rate
[48]. Heart rate data collected during the free-living
period were pre-processed [49] and activity intensity
(J/min/kg) was estimated using a branched equation fra-
mework [47,50]. Resulting time-series data were sum-
marised into physical activity energy expenditure (PAEE,
in kJ/kg/day) and time spent in sedentary and moder-
ate-to-vigorous intensity physical activity (SPA and
MVPA, min/day), whilst minimising diurnal information
bias caused by non-wear periods (segments of non-phy-
siological data). Participants without individual calibra-
tion data but who provided data during free-living were
processed using an age, sex, beta blocker, and sleeping
heart rate adjusted group calibration equation for the
translation of heart rate into activity intensity.
Dietary intake was assessed at baseline and one-year
by plasma vitamin C levels. Vitamin C is not endogen-
ously produced and therefore provides a robust mea-
surement of consumption. Medication adherence was
assessed at one-year by plasma drug levels. Concentra-
tions of metformin, simvastatin and atorvastatin in
plasma samples were measured by liquid-chromatogra-
phy mass-spectrometry (LC-MS/MS) after protein preci-
pitation extraction. The LC-MS/MS methods for
simvastatin and atorvastatin were established at Quoti-
ent Bioresearch Ltd. (Fordham) for the ADDITION-Plus
study. The metformin method was validated at Quotient
Bioresearch Ltd. (Fordham) for a previous study [51].
The calibration ranges for each of the analytes were as
follows: metformin 5.00-5000 ng/mL, simvastatin 0.100-
50.0 ng/mL and atorvastatin 0.0600 to 30.0 ng/mL.
Objective measurement of smoking was assessed by ana-
lysis of cotinine levels in plasma samples using an
Immulite® Nicotine metabolite solid phase competitive
chemiluminescent immunoassay (Siemens).
Self-reported health behaviours
Physical activity was assessed using the validated EPAQ2
[52] and IPAQ [53] questionnaires. Dietary intake was
evaluated using a validated food frequency questionnaire
[54]. Medication adherence was assessed by the Medica-
tion Adherence Report Schedule (MARS) questionnaire
[34]. Smoking status and alcohol consumption were
assessed by questionnaire.
Modelled CVD risk
The UKPDS model [33] uses information on sex, ethni-
city, smoking status, presence or absence of atrial fibril-
lation, systolic blood pressure, HbA1c, total cholesterol,
and HDL-cholesterol to predict the 10-year risk of
primary CVD. Predicted events include myocardial
infarction, sudden cardiac death, other incident ischae-
mic heart disease, stroke, and peripheral vascular disease
death.
Biochemical measures
HbA1c was analysed in venous samples at the time of
diagnostic testing by ion-exchange high-performance
liquid chromatography on a Tosoh machines (Tosoh
Bioscience, Redditch, UK). Serum total cholesterol,
HDL-cholesterol and triglycerides was measured by
means of enzymatic techniques (Dade Behring Dimen-
sion analyser, Newark, USA). Plasma creatinine was ana-
lysed with kinetic colorimetric methods, and urine
albumin by rate nephelemetry (Dade Behring Nephel-
ometer II, Newark, USA). Plasma levels of urea and
electrolytes, bilirubin, alanine aminotansferase (ALT),
aspartate aminotransferase (AST), alkaline phosphatase,
and thyroid stimulating hormone (TSH) and urine levels
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of creatinine were assayed by means of the Dade Behr-
ing Dimension analyser. Metaphosphoric acid was added
to plasma samples for vitamin C analysis before being
stored at -80C°. Plasma vitamin C level was measured
with a Fluoroskan Ascent FL fluorometer. The albumin-
to-creatinine ratio (ACR) was measured on a random
spot urine specimen.
Clinical measures
Blood pressure was calculated as the mean of three
measurements performed after at least 10 minutes rest,
while participants were seated with the cuff on the pre-
dominant arm at the level of the heart, using an auto-
matic sphygmomanometer (Omron M4, UK). ECG was
recorded by a 12 lead machine. Body height and weight
were measured in light indoor clothing and without
shoes using a fixed rigid stadiometer and a scale (SECA,
UK) respectively. Waist circumference was estimated as
the average of two measurements taken with a tape
measure halfway between the lowest point of the rib
cage and the anterior superior iliac crests when stand-
ing. Body fat percentage was measured by bio-electrical
impedance (TANITA, Tokyo, Japan). Angina was
assessed using the Rose angina questionnaire [55]. Neu-
ropathy was evaluated using an adapted version of the
Michigan Neuropathy Screening Instrument [56].
Health utility, functional status, quality of life, well-being,
treatment satisfaction and anxiety
The generic and disease-specific instruments used were
diabetes well-being questionnaire (W-BQ12) [57], SF-36
[58], Audit of Diabetes-Dependent Quality of Life
(ADDQoL) [57], diabetes treatment satisfaction (DTS)
[57], and EuroQol (EQ-5D) [59], and the short form of
the state scale of the Spiegelberger State-Trait Anxiety
Inventory [60]. All patients completed the consultation
and relational empathy (CARE) measure in relation to
the GP and practice nurse; participants in the interven-
tion group also completed this measure in relation to
the lifestyle facilitator [61]. Participants were also asked
to complete six items at one year asking about their
views on the diabetes service they had received in the
last 12 months, including frequency of contact, informa-
tion and advice received, and satisfaction with the ser-
vice. Participants were also asked about the frequency of
and views about self-monitoring of blood glucose using
the Diabetes Glycaemic Education and Monitoring
(DiGem) study questionnaire [62].
Beliefs about behaviour change, illness perceptions,
and habit
A questionnaire, developed according to TPB guidelines
[29,63], assessed selected cognitions about becoming
more physically active, eating a lower fat diet, taking
medication and smoking: intention, perceived beha-
vioural control, and behavioural beliefs. Each construct
was assessed with two items, measured on a 5-point
Likert-type scale ranging from ‘strongly disagree’ to
‘strongly agree’. Examples of perceived control items are:
‘I am confident that I could be more physically active/
eat a lower fat diet in the next 12 months, if I wanted
to’; for intention: ‘I intend to be more physically active/
eat a lower fat diet in the next 12 months’; and for
behavioural beliefs: ‘If I was more physically active/did
eat a lower fat diet in the next 12 months, it is likely
that I would lose weight’. We used the consequences
and treatment control subscales (11 items) of the Illness
Perception Questionnaire-Revised (IPQ-R) [64,65]. The
consequences scale assessed seriousness of diabetes and
the impact of diabetes on various aspects of life. An
example is: ‘My diabetes is a serious condition’. The
treatment control scale assessed beliefs and feelings
associated with the management of diabetes. An exam-
ple is: ‘My treatment can control my diabetes’. Both
scales were measured on 5-point Likert-type scales
ranging from ‘strongly disagree’ to ‘strongly agree’.
Participants were also asked to complete a nine-item
closed-response questionnaire covering basic knowledge
of diabetes and its’ management [66]. At one year, parti-
cipants were asked to write down the most important
change that they had made in their physical activity and
dietary intake, and 12 items were used to assess to what
extent these changes had become a habit [67].
Intervention evaluation
Participants in the intervention group completed 10
items at one year about their views on the frequency of
contacts with the lifestyle facilitators, clarity of advice
given, educational materials, and overall intervention.
They also completed a skills questionnaire assessing
their confidence in relation to using nine skills (e.g.,
goal setting, action planning, self-monitoring) on a 10-
point scale ranging from ‘not at all confident’ to ‘very
confident’, and use of these skills in the past 11 months
in order to increase physical activity, eat a lower-fat
diet, try to stop smoking (if applicable) and try to take
medicines regularly as prescribed (if applicable) on a
binary scale (yes/no).
Costs
Health service use in the three months prior to follow-
up was quantified using an adapted version of the
Health Services Research Unit Aberdeen questionnaire
that enquires about the use of services (consultations
with healthcare professionals and hospitalisations) and
medications [68].
Participant safety
Treatment algorithms were developed with advice from
local diabetes specialists who also contributed to the initial
and follow-up practice-based training sessions for primary
care staff involved in diabetes care. The responsibility for
prescribing and management decisions remained with the
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general practitioners. Classes of medication were only
recommended within licensed indications. Before taking
part in the treadmill test, participants completed a pre-test
screening questionnaire incorporating the Rose angina
questionnaire. If they answered positively to any of the
questions, a short medical review was completed by a clin-
ical member of the team. Blood pressure, current medica-
tions and ECG (if available) were also reviewed following
strict protocols before a participant was allowed to begin
the treadmill test.
Statistical analysis
The additional benefit of the facilitator-led behaviour
change intervention on objective measures of physical
activity level, medication adherence, and change from
baseline in plasma vitamin C and smoking status will be
assessed using an intention to treat analysis comparing
the intervention and comparison groups, using linear
regression for continuous outcomes and a comparison of
proportions for binary outcomes. Continuous outcomes
will be analysed with adjustment for the baseline value of
the outcome, where this has been measured, in order to
improve precision. Those participants missing the base-
line value will remain included in the analysis by using
the missing indicator method, which is valid for pre-
randomisation measures in trials [69]. Due to the large
number of stratifier categories, there will be no adjust-
ment for stratifiers in order to ensure that estimation of
intervention effects is stable. The modelled ten-year car-
diovascular risk will be log transformed before analysis
and computed for those with and without a history of
previous CVD events. The primary intention to treat ana-
lysis will be supported by per protocol analyses of pri-
mary outcomes, where the per protocol population is
defined to be those participants attending the introduc-
tory and initial three core intervention sessions. The
impact of missing primary outcome data will be exam-
ined within sensitivity analyses using the multiple impu-
tation method of Rubin [70]. This will involve fitting an
imputation model from the observed data, from which
missing data will be imputed under two opposing scenar-
ios. In the first scenario it is assumed that the same full
intervention-minus-comparison effect applies amongst
participants with missing data as has been observed
amongst their counterparts with observed data. In the
second scenario it is assumed that the intervention-
minus-comparison effect is zero for participants with
missing data. Ten complete datasets will be imputed, as
recommended, to incorporate the uncertainty in the resi-
duals and parameter estimates of the imputation model.
Subgroup analyses will be confined to the comparison of
intervention effects on primary outcomes by the route of
diagnosis (screen-detected versus already-diagnosed).
The perspective for cost analysis will be the health
service and will include recent use of services (GP/hos-
pital appointments & admissions) and prescribed medi-
cations in the previous 3 months. The costs of intensive
treatment with and without the facilitator-led behaviour
change intervention will be compared with unit change
in health utility. In addition, costs at one-year and future
costs derived from existing data [71] will be compared
with risk of death and cardiovascular events, with appro-
priate sensitivity analysis.
Cohort analyses will be reported separately and will test
causal pathways between behavioural determinants, beha-
viour change and consequences of behaviour change.
Sample size
The trial was designed within the main ADDITION-
Cambridge trial. It was anticipated that 500 patients
would participate in the ADDITION-Plus trial and that
200 individuals per group would be available with follow-
up data. With these numbers, there is 80% power at the
5% level of significance level to detect the following rele-
vant differences between arms in primary outcomes:
Physical activity:
A 0.017 kJ/kg/min difference in PAEE. This is based
on a standard deviation of 0.058 at baseline in the
ProActive trial dataset [72] with mean 0.078. A 0.017
absolute difference represents a 22% relative differ-
ence in mean energy expenditure between groups.
Diet:
A 5.5 umol/l difference in plasma vitamin C (control
group mean 53, SD 19, EPIC study [73]). Adjust-
ment for baseline level in the analysis allows a finer
difference of 4.0 umol/l to be detected between arms
(EPIC test-rest correlation of 0.67).
Medication adherence:
A 10% absolute difference in the proportion of low
adherers to hypoglycaemic medications (control
group 18%, Supported Adherence to Medication
pilot study [51]).
Smoking:
A 9.5% absolute difference in the proportion smok-
ing (control group 17.9%).
Discussion
The ADDITION-Plus trial is designed to establish the
medium-term effectiveness and cost-effectiveness of a
Griffin et al. BMC Public Health 2011, 11:211
http://www.biomedcentral.com/1471-2458/11/211
Page 9 of 12
facilitator-led intervention tailored to support change in
multiple behaviours among intensively-treated indivi-
duals with recently diagnosed diabetes in primary care.
Key features of this trial include (i) a carefully charac-
terised target group and intervention; (ii) an intervention
based on theory and evidence from psychology to sup-
port change in key behaviours affecting CVD risk - phy-
sical activity, dietary intake, medication adherence and
smoking; (iii) quality assured delivery enabled by train-
ing, ongoing supervision and protocols; (iv) objective
measurements of behaviours as well as self-report of
behaviours, functional status and well-being, and; (v) an
examination of the psychological, socio-demographic
and clinical predictors of behaviour change as well as
the clinical consequences of behaviour change in the
cohort.
Results will inform policy recommendations concern-
ing the introduction of health trainer initiatives out-with
the primary-secondary care team to assist in early man-
agement of patients with type 2 diabetes. They will
inform both the education of patients and practitioners,
the quality assurance of behaviour change programmes,
and will improve understanding of the association
between changes in health behaviours and health
outcomes.
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